Biogen and Bio-Thera Report Progress On Tocilizumab

Firms Reveal Positive Phase III Data For Actemra/RoActemra Rival

 
• By Dave Wallace

Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.

Tocilizumab injection syringe
Phase III results for tocilizumab have been positive • Source: Shutterstock

More from Biosimilars

More from Products